Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257918 · ClinicalTrials.gov registry record · Phase 2
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT02257918 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants.
The verdict
NCT02257918, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria. The study is designed to assess the safety and efficacy of an antimicrobial investigational product, AZD0914 manufactured by AstraZeneca, administered to adults to treat uncomplicated urogenital gonorrhea compared to treatment with ceftriaxone. Subjects will be randomly assigned 70:70:40 to receive a single, oral dose of 2000 mg of AZD0914, 3000 mg of AZD0914, or intramuscular dose of 500 mg of ceftriaxone. The drug name is also known as ETX0914.
Interventions
- DRUG Ceftriaxone
- DRUG AZD0914
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2014-11-25 |
| Est. Completion | 2015-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257918
The ClinicalTrials.gov registry entry for NCT02257918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ceftriaxone is the first listed.
NCT02257918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02257918 about?
NCT02257918 is a clinical study titled "Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea". This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria. The study is designed to assess the safety and efficacy of an antimicrobial investigational produc...
What is the current status of trial NCT02257918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2014-11-25. Estimated completion is 2015-12-30.
What interventions are being tested in trial NCT02257918?
The interventions under investigation include: Ceftriaxone (DRUG), AZD0914 (DRUG).
Who is sponsoring clinical trial NCT02257918?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.